Yes, what I can say about IBC, it’s really, it’s very personal journey also with this rare cancer. And it is, I really want to start this, my topic about this, about this IBC by saying that in Europe, IBC, it’s not known as a rare cancer. And in the US, it is known as a rare cancer. So we need to start from this. It’s very important to be known as a rare cancer...
Yes, what I can say about IBC, it’s really, it’s very personal journey also with this rare cancer. And it is, I really want to start this, my topic about this, about this IBC by saying that in Europe, IBC, it’s not known as a rare cancer. And in the US, it is known as a rare cancer. So we need to start from this. It’s very important to be known as a rare cancer. It’s a call to action. I also would say that many patients experience symptoms like redness, swelling or skin changes, but they are misdiagnosed with infections or inflammation. They go through rounds of antibiotics. And by going through these steps, it’s very difficult then to go to the diagnosis early. And timing, we know, in breast cancer diagnosis is crucial. It’s very important. So it is very important to be aware of these kind of cases and not to misdiagnose. And when a patient can come with redness or swelling or with all these kind of symptoms, let us say, it is very important to include the team, a multidisciplinary team. As a patient, it’s not just the tumor. It’s about the fear, the side effects, the sudden disruptions of your life, work, family, body image, future plans and all these things. But as I said earlier, it’s very important for early clinical recognition for this cancer, especially here in Europe.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
